<DOC>
	<DOCNO>NCT00143520</DOCNO>
	<brief_summary>This 6-month study evaluate effect monotherapy rivoglitazone , insulin sensitizer , glycemic control newly identify type 2 diabetic diabetic adequately treat antidiabetic agent . The study test rivoglitazone us placebo active treatment group comparison .</brief_summary>
	<brief_title>Placebo Active Controlled Study Rivoglitazone Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Type 2 diabetes male female patient Between 18 75 year age With HbA1c great equal 7.5 % le 10.5 % randomization Type 1 diabetic type 2 diabetic currently insulin therapy Patients unwilling unable discontinue antidiabetic medication ( ) History ketoacidosis History therapy rosiglitazone , troglitazone , pioglitazone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Placebo active control dose response study rivoglitazone type 2 diabetic</keyword>
</DOC>